Engerix-b, hepatitis b vaccine (recombinant dna adsorbed) _ epharmapedia

Engerix B is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes in non immune subjects. Hepatitis c patient education The categories within the population to be immunised are determined on the basis of official recommendations.

It can be expected that hepatitis D will also be prevented by immunisation with Engerix B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.


Engerix B should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous Engerix B administration.

As with other vaccines, the administration of Engerix B should be postponed in subjects suffering from acute severe febrile illness. Hepatitis c virus vaccine The presence of a minor infection, however, is not a contra-indication for immunisation

Common: drowsiness, headache in adults (headache is very common in children)

Common: gastrointestinal symptoms (such as nausea, vomiting, diarrhoea, abdominal pain)

Common: fever (> 37.5°C), malaise, swelling at injection site, injection site reaction (such as induration)

Encephalitis, encephalopathy, convulsions, paralysis, neuritis, (including Guillain-Barre syndrome, optic neuritis and multiple sclerosis) neuropathy, hypoaesthesia

Apnoea in very premature infants ( 28 weeks of gestation) (see section 4.4)

Anaphylaxis, allergic reactions including anaphylactoid reactions and mimicking serum sickness

The simultaneous administration of Engerix B and a standard dose of HBIg does not result in lower anti-HBs antibody titres provided that they are administered at separate injection sites.

Engerix B can be given concomitantly with Haemophilus influenzae b, BCG, hepatitis A, polio, measles, mumps, rubella, diphtheria, tetanus and pertussis vaccines.

Different injectable vaccines should always be administered at different injection sites.

Engerix B may be used to complete a primary immunisation course started either with plasma-derived or with other genetically-engineered hepatitis B vaccines, or, if it is desired to administer a booster dose, it may be administered to subjects who have previously received a primary immunisation course with plasma-derived or with other genetically-engineered hepatitis B vaccines

Because of the long incubation period of hepatitis B it is possible for unrecognised infection to be present at the time of immunisation. Treatment for hepatitis c The vaccine may not prevent hepatitis B infection in such cases.

The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E viruses.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

A number of factors have been observed to reduce the immune response to hepatitis B vaccines. Medication for hepatitis c cure These factors include older age, male gender, obesity, smoking, route of administration and some chronic underlying diseases. How can you get hepatitis c from someone else Consideration should be given to serological testing of those subjects who may be at risk of not achieving seroprotection following a complete course of Engerix B. Symptoms for hepatitis c Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.

Patients with chronic liver disease or with HIV infection or hepatitis C carriers should not be precluded from vaccination against hepatitis B. Hepatitis c vaccine price in pakistan The vaccine could be advised since HBV infection can be severe in these patients : the HB vaccination should thus be considered on a case by case basis by the physician. What is the hepatitis c In HIV infected patients, as also in patients with renal insufficiency including patients undergoing haemodialysis and persons with an impaired immune system, adequate anti-HBs antibody titres may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine.

Engerix B should not be administered in the buttock or intradermally since this may result in a lower immune response.

Engerix B should under no circumstances be administered intravenously.

As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunization series to very premature infants born < 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. Hepatitis c etiology As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

The effect of the HBsAg on foetal development has not been assessed.

However, as with all inactivated viral vaccines one does not expect harm for the foetus. Hepatitis c yellow skin Engerix B should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus.

The effect on breastfed infants of the administration of Engerix B to their mothers has not been evaluated in clinical studies, as information concerning the excretion into the breast milk is not available.

Leave a Reply

Your email address will not be published. Required fields are marked *